AstraZeneca's Calquence plus chemoimmunotherapy approved in EU to treat adult patients with previously untreated mantle ...
AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous …